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Interaction of GABA and Excitatory Amino Acids in the Basolateral
Amygdala: Role in Cardiovascular Regulation
Robert P. Soltis, Jennifer C. Cook, Adam E. Gregg, and Brian J. Sanders
Departments of Pharmaceutical Sciences and Psychology, Drake University, Des Moines, Iowa 50311
Activation of the amygdala in rats produces cardiovascular
changes that include increases in heart rate and arterial
pressure as well as behavioral changes characteristic of
emotional arousal. The objective of the present study was to
examine the interaction of GABA and excitatory amino acid
(EAA) receptors in the basolateral amygdala (BLA) in regu-
lating cardiovascular function. Microinjection of the GABAA
receptor antagonist bicuculline methiodide (BMI) or the E A A
receptor agonists NMDA or AMPA into the same region of the
BLA of conscious rats produced dose-related increases in
heart rate and arterial pressure. Injection of the nonselective
EAA receptor antagonist kynurenic acid into the BLA pre-
vented or reversed the cardiovascular changes caused by
local injection of BMI or the noncompetitive GABA antago-
nist picrotoxin. Conversely, local pretreatment with the glu-
tamate reuptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylic
acid enhanced the effects of intra-amygdalar injection of BMI.
The cardiovascular effects of BMI were also attenuated by
injection of either the NMDA antagonist 3-(2-carboxypiperazin-
4-yl)-propyl-1-phosphonic acid (CPP) or the AMPA receptor an-
tagonist 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-
7-sulfonamide (NBQX). When these two EAA receptor antagonists
were combined, their ability to suppress BMI-induced tachycardic
and pressor responses was additive. These findings indicate that
the cardiovascular effects caused by blockade of GABAergic in-
hibition in the BLA of the rat are dependent on activation of local
NMDA and AMPA receptors.
Key words: basolateral amygdala; excitatory amino acids;
NMDA; AMPA; bicuculline; kynurenic acid; L-trans-PDC; heart
rate; arterial pressure; cardiovascular control
The amygdala is thought to play a central role in a variety of
behavioral, physiological, and endocrine responses. A significant
body of evidence supports the view that the amygdala is an
important component of central cardiovascular control mecha-
nisms. Neuroanatomic studies indicate that the amygdala shares
reciprocal connections to other areas of the CNS involved in
cardiovascular control, including hypothalamic nuclei, the dorso-
motor nucleus of the vagus, and the periaqueductal gray (Hopkins
and Holstege, 1978; Krettek and Price, 1978; Beitz, 1982). Elec-
trical stimulation of various sites in the amygdala evokes increases
in heart rate and arterial pressure characteristic of the defense
reaction (Hilton and Zbrozyna, 1963; Galeno and Brody, 1983;
Gelsema et al., 1987, Maskati and Zbrozyna, 1989), whereas
lesioning of this area can prevent stress-induced cardiovascular
changes (Galeno et al., 1984; Sanders et al., 1994) and the devel-
opment of hypertension (Galeno and Brody, 1982). More re-
cently, it has been shown that injection of GABA antagonists into
the anterior region of the basolateral amygdala (BLA) elicits
increases in heart rate and arterial pressure (Sanders and Shek-
har, 1991, 1995; Sanders et al., 1995). Thus, the BLA appears to
contain a population of neurons that can elicit significant cardio-
vascular changes, and it appears that these neurons are under
tonic GABAergic inhibition.
As yet, the excitatory input to neurons in the BLA that gener-
ate these cardiovascular changes has not been defined. GABA
and EAA receptors mediate the majority of inhibitory and exci-
tatory synaptic transmission in the mammalian CNS and interact
to modulate neuronal activity in several brain nuclei (Jones, 1988;
Steward et al., 1990; Soltis and DiMicco, 1991b), including the
BLA (Rainnie et al., 1991a,b; Gean and Chang, 1992). Recent
behavioral studies suggest a functional role for an interaction
between GABA and EAA receptors in the BLA. Injection of
GABA antagonists into the BLA can elicit anxiogenic behavior
(Sanders and Shekhar, 1995) whereas, conversely, injection of
EAA receptor antagonists into this same region can block the
acquisition and expression of conditioned fear (Campeau et al.,
1992; Falls et al., 1992; Kim et al., 1993; Campeau and Davis,
1995; Maren et al., 1996). If a similar relationship between GABA
and EAA systems exists in the BLA with respect to cardiovascu-
lar function, then the cardiovascular changes caused by blockade
of GABAergic inhibition in the BLA will depend on activation of
local EAA receptors. To test this hypothesis, the EAA receptor
agonists NMDA and AMPA and the postsynaptic GABAA an-
tagonists bicuculline methiodide (BMI) and picrotoxin were in-
jected into the region of the BLA of conscious rats while moni-
toring heart rate and arterial pressure. The effects of the GABA
antagonists then were tested in the presence of the nonselective
EAA receptor antagonist kynurenic acid (KYN) or the glutamate
reuptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylic acid (PDC).
In addition, the role of specific subtypes of EAA receptors in
generating the cardiovascular response to the GABA antagonist
BMI was examined using the NMDA receptor antagonist 3-(2-
carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP) and the
AMPA receptor antagonist 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-
benzo[f]quinoxaline-7-sulfonamide (NBQX).
MATERIALS AND METHODS
Male Sprague Dawley rats (270–350 gm, Harlan Sprague Dawley, Indi-
anapolis, IN) were used in all experiments. Animals were housed indi-
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vidually under controlled temperature and light periodicity with free
access to food and water. All procedures used were approved by Drake
University Animal Care and Use Committee and followed guidelines set
forth in the National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Stereotaxic surgery. On day one of the surgical protocol, rats were
anesthetized with Avertin (10 ml/kg, i.p.) and positioned in a stereotaxic
frame (Kopf Instruments) with the incisor bar positioned at 23.3 mm
below the horizontal plane. Rectal temperature was monitored and
maintained at 36–37°C with a heating pad. Once the overlying skin and
connective tissue were cleared from the skull, holes were drilled into the
skull to allow access to the brain. Chronic guide cannulae (26 gauge, 11
mm length, Plastics One, Roanoke, VA) were directed bilaterally at the
BLA (AP 22.1, RL 6 4.9, HD 28.7) and cemented in place with
cranioplastic cement anchored to the skull with three jeweler’s screws.
The guide cannulae were fitted with injector cannulae (33 gauge, 12 mm
length) during the implantation procedure to prevent fluids and tissue
from accumulating in the guide cannulae. After the cranioplastic cement
had set, the injector cannulae were removed and the guide cannulae were
sealed with wire dummy cannulae. Animals were removed from the
stereotaxic frame and allowed to recover in individual cages.
Cardiovascular instrumentation. Five to seven days after implantation
of the guide cannulae, animals were re-anesthetized with Avertin. The
right femoral artery was cannulated with a 3.5 cm length of Microre-
nathane tubing (0.01 inner diameter, Braintree Scientific, Braintree,
MA) attached to a length of Tygon tubing (0.02 inner diameter) filled
with heparinized saline (100 U/ml), and the end was sealed with a stylet.
The tubing was then routed subcutaneously to the nape of the neck,
exteriorized, and secured to skin and underlying muscle with suture. The
animals were allowed to recover in their individual cages for 24–48 hr
before testing. By this time, the animals had resumed their regular
eating, drinking, and grooming habits and exhibited no signs of pain or
stress.
Microinjection procedure. Animals were tested while freely moving or
resting in their home cage between 10:00 A.M. and 4:00 P.M. Arterial
pressure was measured and recorded by connecting the arterial line in
series to a pressure transducer, a MacLab/4 data acquisition system, and
a Macintosh LCIII computer. Heart rate was derived from the arterial
pulse pressure and was measured and recorded on a separate channel.
Once a steady baseline of cardiovascular parameters was attained, the
injector cannulae containing drug solution or vehicle were inserted into
the guide cannulae. All injections were bilateral (250 nl /side, infused
over 30 sec) and were made using two 5 ml Hamilton syringes mounted
in a Harvard infusion pump. Injection cannulae remained in place for 1
min after ending the infusion and then removed. The order of injections
was given in a staggered or varied sequence to control for order effects.
Animals received no more than two injections per day and no more than
five injections at one site.
Histology. Microinjection sites were marked at the completion of each
study. After induction of anesthesia (10 ml/kg Avertin, i.p.), 250 nl of a
5% solution of Alcian blue dye was infused at each site. The brain was
perfused transcardially with 60 ml of heparinized saline followed by 150
ml of buffered 10% Formalin. The brain was removed and stored in
buffered 10% Formalin. Coronal sections (60 mm) were cut on a mic-
rotome/cryostat, mounted on gelatin-coated slides, and stained with 1%
neutral red solution. The locations of the sites of injection were deter-
mined according to the atlas of Paxinos and Watson (1986).
Chemicals. Drugs used in these experiments included BMI, NMDA,
AMPA, PDC, CPP, NBQX (Research Biochemicals, Natick, MA), pic-
rotoxin, KYN, and xanthurenic acid (Sigma, St. Louis, MO). All drugs
were dissolved in saline, and the final pH was adjusted to 6–8. The
anesthetic Avertin was prepared as follows: 10 gm of tribromoethanol
(Aldrich, Milwaukee, WI), 5 gm tert-amyl alcohol (Sigma); 10 ml of this
concentrate was dissolved in 40 ml of absolute ethanol and 450 ml of
0.9% saline/0.1 M phosphate buffer, pH 7.2 (Inglis et al., 1993).
Statistics. Results are expressed as mean 6 SEM. In those experiments
in which the data are expressed as a time course, the data were analyzed
after calculation of the area under the curve (AUC). The AUC was
determined for each experiment by plotting the data (change from
baseline) over a grid (grid block 5 5 min 3 mmHg or beats/min) and
calculating the area using the trapezoidal method. All grids for a given
experiment were summed (including both positive and negative areas,
relative to baseline) to determine the total AUC (Feldman and Bucca-
fusco, 1997). In those experiments in which the data are expressed as
peak changes in heart rate or arterial pressure, the peak was defined as
the highest value sustained for 1 min or longer. These values (AUCs and
peak changes) were analyzed using one way ANOVA (with repeated
measures where appropriate) using dose as the factor. Scheffe´’s post hoc
test was used to determine differences between groups; p , 0.01 was
considered significant.
RESULTS
Bilateral injection of the GABA antagonist BMI (10–100 pmol)
or the EAA agonists NMDA (10–100 pmol) or AMPA (3–30
pmol) into the BLA of conscious rats produced dose-related
increases in heart rate and arterial pressure (Figs. 1–4). The time
course of these changes was similar between the EAA agonists
NMDA and AMPA in that the onset of effects occurred within
1–5 min of injection, peaked at 7–10 min, and returned to baseline
by 25 min. Similarly, 100 pmol of NMDA produced maximal
changes in heart rate (180 6 10 beats/min) and arterial pressure
(11 6 2 mmHg) that were not significantly different from 30 pmol
of AMPA (170 6 9 beats/min and 114 6 1 mmHg, respectively).
However, at a dose of 100 pmol, AMPA produced significantly
smaller changes in heart rate (134 6 10, n 5 6) and arterial
pressure (13 6 4 mmHg) compared with the 30 pmol dose.
Higher doses of NMDA were not systematically studied because
of seizure-like activity in one rat after a 300 pmol injection of
NMDA. The tachycardic and pressor responses to injection of
Figure 1. Tracings of heart rate (HR; beats/min) and arterial pressure
(AP; mmHg) from four conscious, chronically instrumented rats depicting
the effects of bilateral microinjection of Saline, BMI, AMPA, and NMDA
into the basolateral amygdala. Drugs were injected in a volume of 250
nl/side over 30 sec. Vertical lines indicate the start of injection.
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BMI had a similar time to onset as the EAA agonists. However,
the cardiovascular responses to BMI were of greater magnitude
and of longer duration compared with the EAA agonists. The
baseline heart rates (345 6 11 beats/min) and mean arterial
pressures (110 6 4 mmHg) for this series of experiments were not
significantly different among the groups of animals.
Microinjection of either EAA agonist or BMI also produced
changes in locomotor activity. Although not quantitated, these
changes included intermittent running and moving of bedding
and appeared to follow the time course of the cardiovascular
changes. However, in many animals, because the activity was
intermittent, the heart rate and arterial pressure were consistently
elevated during the active and quiescent periods in these rats.
After histological examination of the brains from the above
experiments, the injection sites were found to be within the
coronal planes lying 1.8–2.6 mm posterior to bregma. The sites at
which BMI, NMDA, and AMPA produced increases in heart
rate and arterial pressure overlapped each other and were local-
ized to areas within or 0.3 mm dorsal or lateral to the BLA (Fig.
5). To verify further that the BLA was the probable site of action
of these agents, 10 animals were implanted with chronic guide
cannulae directed at sites 0.5–1.5 mm medial or dorsal to the BLA
(Fig. 5). Two of these sites are not identified in Figure 5 because
the sites of injection were located in coronal planes anterior to
those depicted in the figure. Each animal received injections of
BMI (100 pmol), NMDA (100 pmol), and AMPA (30 pmol) at
each of these sites. In all cases, injection of either of the agents
failed to produce a tachycardic response greater than 25 beats/
min or a pressor response greater than 5 mmHg. At three sites at
which an increase in heart rate of 20–25 beats/min was observed,
the onset was greater than 5 min.
Given that stimulation of EAA receptors and blockade of
GABA receptors at the same site in the BLA can produce similar
changes in cardiovascular function, the next series of experiments
Figure 2. Cardiovascular effects of intra-amygdalar injection of bicuculline
methiodide. Time course of changes in heart rate (HR; beats/min; top) and
mean arterial pressure (MAP; mmHg; bottom) in conscious, chronically
instrumented rats after bilateral injection of saline (250 nl/side) or various
doses of bicuculline methiodide into the basolateral amygdala. The 30 pmol
and 100 pmol doses for both HR and MAP are significantly different from
saline. Each dose, n 5 5. HR: F(3,16) 5 66.23; MAP: F(3,16) 5 34.99.
Figure 3. Cardiovascular effects of intra-amygdalar injection of AMPA.
Time course of changes in heart rate (HR; beats/min; top) and mean arterial
pressure (MAP; mmHg; bottom) in conscious, chronically instrumented rats
after bilateral injection of saline (250 nl/side) or various doses of AMPA
into the basolateral amygdala. The 10 pmol and 30 pmol doses for both HR
and MAP are significantly different from saline. AMPA (30 pmol), n 5 6;
all other doses, n 5 4. HR: F(3,14) 5 20.19; MAP: F(3,14) 5 5.77.
Soltis et al. • Amygdala GABA and EAA Receptors and CV Regulation J. Neurosci., December 1, 1997, 17(23):9367–9374 9369
examined the role of local EAA receptors in mediating the cardio-
vascular changes observed after injection of GABA antagonists
into the BLA. Coinjection of the nonselective EAA receptor
antagonist KYN (1–10 nmol) into the BLA blocked in a dose-
dependent manner the increases in heart rate and arterial pressure
seen with BMI 100 pmol (Fig. 6). Coinjection of 100 pmol of BMI
and 10 nmol of xanthurenic acid, a compound chemically similar to
KYN with no activity at EAA receptors (Guyenet et al., 1987),
produced increases in heart rate (124 6 12 beats/min) and arterial
pressure (18 6 3 mmHg) similar to those produced by 100 pmol of
BMI alone (134 6 9 beats/min and 20 6 1 mmHg, respectively; Fig.
2). Intra-amygdalar injection of KYN (10 nmol) alone produced no
significant changes in baseline heart rate (15 6 8 beats/min) or
arterial pressure (12 6 3 mmHg) (n 5 4).
In another series of experiments, we examined the effects of
KYN using a different GABA antagonist and a different micro-
injection protocol. Microinjection of 100 pmol of picrotoxin, a
noncompetitive, postsynaptic GABAA antagonist, produced sig-
nificant increases in heart rate and arterial pressure similar to
those seen with local injection of BMI (Fig. 7). Microinjection of
10 nmol of KYN into the BLA 5 min after local injection of
picrotoxin reversed the picrotoxin-induced tachycardic and pres-
sor responses. Injection of the inactive analog xanthurenic acid
did not alter significantly the magnitude or time course of cardio-
vascular changes produced by picrotoxin.
Given that blockade of EAA receptors in the BLA can prevent
or reverse the cardiovascular changes seen with removal of local
GABAergic inhibition, the next series of experiments examined
whether potentiation of local glutamatergic transmission would
enhance the cardiovascular changes observed after injection of
GABA antagonists into the BLA. Microinjection of the gluta-
mate reuptake inhibitor PDC into the BLA (followed 5 min later
with a local injection of saline) did not produce any significant
changes in heart rate or arterial pressure (Fig. 8). Injection of an
intermediate dose of BMI (30 pmol; preceded 5 min earlier with
a local injection of saline) produced modest but significant in-
Figure 4. Cardiovascular effects of intra-amygdalar injection of NMDA.
Time course of changes in heart rate (HR; beats/min; top) and mean
arterial pressure (MAP; mmHg; bottom) in conscious, chronically instru-
mented rats after bilateral injection of saline (250 nl/side) or various doses
of NMDA into the basolateral amygdala. The 30 pmol and 100 pmol doses
for both HR and MAP are significantly different from saline. Each dose,
n 5 4. HR: F(3,12) 5 58.54; MAP: F(3,12) 5 21.14.
Figure 5. Schematic representation of injection sites in coronal sections
through the basolateral amygdala. Filled circles represent sites at which
100 pmol of BMI increased heart rate by 50 beats/min or greater. Filled
triangles represent sites at which 30 pmol of AMPA increased heart rate
by 30 beats/min or greater. Filled squares represent sites at which 100 pmol
of NMDA increased heart rate by 30 beats/min or greater. Open diamonds
represent sites at which BMI, AMPA, and NMDA failed to increase heart
rate by 25 beats/min or more. ACo, Anterior cortical amygdaloid nucleus;
BLA, basolateral amygdaloid nucleus; BLV, ventral basolateral amygdal-
oid nucleus; BMA, anterior basomedial amygdaloid nucleus; CNA, central
amygdaloid nucleus; DEn, dorsal endopiriform nucleus; IM, main inter-
calated amygdaloid nucleus; LaDL, dorsolateral lateral amygdaloid nu-
cleus; OT; optic tract; Pir, piriform cortex; PLCo, posterolateral cortical
amygdaloid nucleus; PVN, paraventricular nucleus of the hypothalamus;
VMH, ventromedial hypothalamus; 3V, third ventricle. Adapted from the
atlas of Paxinos and Watson (1986).
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creases in heart rate (164 6 9 beats/min) and arterial pressure
(114 6 2 mmHg). However, when this intermediate dose of BMI
was preceded by a local injection of the glutamate reuptake
inhibitor PDC, the response to BMI was significantly potentiated
(1130 6 15 beats/min and 124 6 5 mmHg, respectively).
The ability of a glutamate receptor antagonist to block or
reverse the cardiovascular effects of GABA antagonists and the
ability of a glutamate reuptake inhibitor to enhance these same
effects suggest that local EAA receptors play a role in this
response. To examine the role of EAA receptor subtypes in these
changes, the NMDA receptor antagonist CPP and the AMPA
receptor antagonist NBQX were used. Coinjection of either 100
pmol of CPP or 100 pmol of NBQX with 50 pmol of BMI into the
BLA attenuated, to a similar extent, the tachycardic and pressor
responses associated with BMI (Fig. 9). Furthermore, in the
presence of the two EAA receptor antagonists, the changes in
heart rate and arterial pressure observed with BMI were reduced
further compared with BMI in the presence of either antagonist
alone, suggesting that the effects of the two EAA antagonists
were additive.
DISCUSSION
Data presented in this study provide evidence that the cardiovas-
cular effects resulting from blockade of GABAergic inhibition in
the BLA of conscious rats are dependent on activation of local
Figure 6. Kynurenic acid blocks the cardiovascular response to BMI.
Time course of changes in heart rate (HR; beats/min; top) and mean
arterial pressure (MAP; mmHg; bottom) in conscious, chronically instru-
mented rats after bilateral, intra-amygdalar coinjection of 100 pmol BMI
with either xanthurenic acid (XAN ) or kynurenic acid (KYN ). The
changes in HR and MAP for BMI 1 KYN (3.0 nmol) and for BMI 1
KYN (10 nmol) are significantly different compared with BMI 1 XAN
and BMI 1 KYN (1.0 nmol). BMI 1 XAN and BMI 1 KYN (10 nmol),
n 5 5; all others, n 5 4. HR: F(3,14) 5 25.70; MAP: F(3,14) 5 21.86.
Figure 7. Kynurenic acid reverses the cardiovascular response to picro-
toxin. Time course of changes in heart rate (HR; beats/min; top) and mean
arterial pressure (MAP; mmHg; bottom) in conscious, chronically instru-
mented rats after bilateral, intra-amygdalar injection of picrotoxin (Picro;
100 pmol) without further treatment and picrotoxin followed by injection
of xanthurenic acid (XAN; 10 nmol) or kynurenic acid (KYN; 10 nmol).
The changes in HR and MAP for Picro 1 KYN are significantly different
compared with Picro alone and Picro with XAN. Picro only, n 5 4; all
others, n 5 3. HR: F(2,7) 5 22.74; MAP: F(2,7) 5 14.60.
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EAA receptors. This study is consistent with and expands on
previous reports indicating that GABA and EAA receptors in the
amygdala play an important role in anxiogenic behavior and,
additionally, provides functional support of previous work de-
scribing the GABA/EAA receptor interactions in the amygdala
at the cellular level.
Microinjection of the EAA receptor agonists NMDA and
AMPA into the BLA produced dose-related increases in heart
rate and arterial pressure similar to those produced by injection of
the GABAA receptor antagonist BMI at the same site. This
pattern of cardiovascular changes is consistent with anxiety-like
or defense-like reactions in this species (Hilton and Zbrozyna,
1963; Hilton and Redfern, 1986). Interestingly, the dose–re-
sponse curve to AMPA was bell-shaped in that at higher doses
the tachycardic and pressor responses were significantly dimin-
ished. This observation is consistent with other reports demon-
strating that higher doses or concentrations of ionotropic EAA
agonists can produce changes that are opposite or inhibitory to
those seen at lower concentrations (Lipski et al., 1988; Soltis and
DiMicco, 1991a). It has been postulated that the mechanism of
this diminished response is associated with either receptor de-
sensitization or depolarization blockade (Lipski et al., 1988; Otis
et al., 1996).
The sites from which injection of BMI, NMDA, and AMPA
elicited the greatest increases in heart rate and arterial pressure
were localized to the anterior portions of the BLA. It can be
argued that the volume of injection (250 nl) used in the present
study does not restrict the drug to the BLA exclusively. Indeed,
histological examination of the injection sites after infusion of the
dye Alcian blue indicates that the dye, a crude estimator of drug
diffusion, does spread, in some cases, to nuclei adjacent to the
BLA. Although there are no definitive methods by which to
determine the exact site of action of a drug after its injection into
the brain, we attempted to establish the boundaries of the reac-
tive area by implanting cannulae at sites near the proposed active
site. Areas dorsal to the active site were examined based on the
Figure 8. PDC potentiates the cardiovascular response to BMI. Maximal
changes in heart rate (HR; beats/min; top) and mean arterial pressure
(MAP; mmHg; bottom) in conscious, chronically instrumented rats after
bilateral, intra-amygdalar injection of L-trans-pyrrolidine-2,4-dicarboxylic
acid (PDC; 1 nmol) and saline (Sal; 250 nl), saline and BMI (30 pmol), or
PDC and BMI. Single asterisks denote significant differences from PDC/
saline. Double asterisks denote significant differences from saline/BMI.
Each group, n 5 4. HR: F(2,9) 5 42.88; MAP: F(2,9) 5 33.71.
Figure 9. CPP and NBQX block the cardiovascular response to BMI.
Maximal changes in heart rate (HR; beats/min; top) and mean arterial
pressure (MAP; mmHg; bottom) in conscious, chronically instrumented
rats after bilateral injection of 50 pmol of BMI alone or coinjection of
BMI with CPP (BMI 1 CPP; 100 pmol), NBQX (BMI 1 NBQX; 100
pmol), or CPP and NBQX (BMI 1 CPP 1 NBQX ). Single asterisks
denote significant differences from BMI alone. Double asterisks denote
significant differences from BMI alone, BMI 1 CPP, and BMI 1 NBQX.
BMI alone, n 5 8; all others, n 5 5. HR: F(3,19) 5 15.30; MAP: F(3,19) 5
23.22.
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cannula tract (located dorsally) representing the path of least
resistance for drug diffusion and, therefore, a likely site of action.
Areas medial to the BLA were examined because this area
includes the central nucleus of the amygdala (CNA), a site where
electrical stimulation produces cardiovascular and behavioral
changes that replicate the defense reaction (Hilton and
Zbrozyna, 1963; Galeno and Brody, 1983; Gelsema et al., 1987).
In this study, the areas medial and dorsal to the BLA were clearly
nonreactive to BMI, NMDA, or AMPA at the doses tested. It is
possible that the CNA is the active site and that the doses used in
the present study were too high to elicit a response when injected
directly at the active site. That is, the cardiovascular responses
attributed to injection of these agents into the BLA may actually
be a result of the drugs diffusing to the CNA at a lesser but
pharmacologically active concentration. However, if the CNA
were the site of action and the doses used were too high to
produce an effect when injected directly into the CNA, then those
injections that were medial to the CNA (see Fig. 5) should have
produced tachycardic and pressor responses similar to those seen
after injections at sites an equal distance lateral to the CNA, that
is, in the BLA. Given that this did not occur, the histological data
suggest that the anterior region of the BLA is the site of action of
these agents. This pattern of localization and the description of
cardiovascular changes associated with injection of these agents
are consistent with previous reports that used similar volumes of
injections to demonstrate that intra-amygdalar injections of
GABAA antagonists and glutamate produce stress-like cardiovas-
cular changes (Maskati and Zbrozyna, 1989; Sanders and Shek-
har, 1991, 1995).
The coincident site of injection and the similar pattern and onset
of cardiovascular changes seen with injection of NMDA, AMPA,
and BMI suggest that these agents are activating the same popu-
lation of neurons to generate the cardiovascular changes. To de-
termine whether the cardiovascular responses to intra-amygdalar
injection of GABA antagonists are mediated by local EAA recep-
tors, the nonselective EAA receptor antagonist KYN was used.
When coinjected with BMI, KYN attenuated in a dose-dependent
manner the tachycardic and pressor responses. Similarly, microin-
jection of KYN 5 min after injection of the GABA antagonist
picrotoxin reversed the tachycardic and pressor effects caused by
this agent. Conversely, xanthurenic acid, a structural analog of
KYN without significant effects on EAA receptors (Guyenet et al.,
1987), failed to alter the response when coinjected with BMI or
locally injected 5 min after picrotoxin. Therefore, taking together
the staggered order of treatments within the series of experiments,
the negative control using xanthurenic acid, and the different in-
jection protocols (coinjection versus reversal with a separate injec-
tion), it is likely that the reduced response observed in the presence
of KYN can be attributed to blockade of EAA receptors and not
to changes in the responsiveness of the preparation or to nonspe-
cific actions of KYN.
To characterize further the interaction of GABA- and EAA-
mediated synaptic transmission in the BLA in regulating cardio-
vascular function, we used the glutamate reuptake inhibitor PDC
(Bridges et al., 1991). We hypothesized that if antagonism of local
EAA receptors can block the effects of a GABA antagonist, then
enhancing activity at local EAA receptors should potentiate the
effects of a GABA antagonist. To demonstrate an enhanced effect
of BMI, we used an intermediate dose of BMI (30 pmol) as
determined in the dose–response experiments. Injection of PDC
at a dose (1 nmol) shown to be capable of producing cardiore-
spiratory changes after microinjection into the medulla (Mc-
Manigle et al., 1995) did not produce significant changes in
resting heart rate or arterial pressure. However, when injected
before BMI, PDC potentiated the response to BMI to a magni-
tude otherwise seen only with the 100 pmol dose of BMI. Thus,
the effects of PDC in combination with BMI are consistent with
a role for EAA receptor-mediated transmission in BMI-induced
cardiovascular changes. However, EAA receptor-mediated input
does not appear to play an important role in regulating cardio-
vascular function under basal conditions, as evidenced by the lack
of effect after injection of PDC or KYN alone. Rather, it appears
that the predominate tone in the BLA under basal conditions in
conscious rats is GABA-mediated inhibition.
In the final series of experiments, we examined the role of
specific EAA receptor subtypes in mediating the cardiovascular
responses after blockade of GABAergic inhibition in the BLA.
Injection of either the NMDA receptor antagonist CPP or the
AMPA receptor antagonist NBQX attenuated the tachycardic
and pressor responses to a similar degree. When the two EAA
antagonists were combined and coinjected with BMI, the effects
were additive. Therefore, there appear to be two distinct compo-
nents mediating the cardiovascular response to injection of BMI.
One component relies on activity at NMDA receptors, whereas
the other is mediated through AMPA receptors. The notion that
neuronal excitability in the BLA can be modulated by a balance
between EAA receptor-mediated excitation and GABA receptor-
mediated inhibition has been investigated using other prepara-
tions. Intracellular recordings from brain slices have shown that
stimulation of afferent pathways to the BLA elicits EPSPs con-
sisting of fast and slow components that are blocked by AMPA/
kainate receptor antagonists and NMDA receptor antagonists,
respectively (Rainnie et al., 1991a; Gean and Chang, 1992).
Furthermore, in the presence of bicuculline, epileptiform burst
discharges occur in normally quiescent BLA neurons, suggesting
that the overriding input to the neurons is GABAA receptor-
mediated inhibition (Rainnie et al., 1991b). In the present study,
we have provided in vivo evidence that a similar interaction
between GABA and EAA systems in the BLA plays a role in
cardiovascular regulation.
The present study is also important in light of recent studies
examining the role of GABA and EAA receptors in the BLA
with respect to anxiogenic behavior. Injection of NMDA and
non-NMDA EAA receptor antagonists into the BLA blocks in a
dose-dependent manner the acquisition and the expression, re-
spectively, of conditioned fear (Campeau et al., 1992; Falls et al.,
1992; Kim et al., 1993; Campeau and Davis, 1995; Maren et al.,
1996). Furthermore, injection of GABA antagonists into the
BLA elicits anxiogenic behavior as measured in various behav-
ioral paradigms (Sanders and Shekhar, 1995). Therefore, these
studies and the data presented here suggest that an interaction
between GABA and EAA receptors in the BLA may control the
cardiovascular responses associated with conditioned rewarding
or aversive stimuli.
In summary, the present study provides evidence that the
cardiovascular response caused by removal of GABAergic inhi-
bition in the BLA is dependent on activation of local EAA
receptors. Therefore, the neurons mediating this response are
regulated by a balance of GABA receptor- and EAA receptor-
mediated synaptic transmission.
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